Pfizer Names Chris Boshoff as Chief Scientific Officer
Slice of Healthcare Team
Nov 26, 2024
Key Highlights
- Dr. Chris Boshoff to lead Pfizer’s R&D from January 2025, succeeding Dr. Mikael Dolsten.
- Roger Dansey named Interim Chief Oncology Officer, with Johanna Bendell joining as Chief Development Officer, Oncology.
- Dr. Boshoff’s legacy includes delivering 24 approved medicines in over 30 indications.
Source: Business Wire
Notable Quotes
“ Chris has a compelling vision for the future of R&D at Pfizer…Under Chris’ leadership, Oncology has become one of Pfizer’s most productive divisions. ”
Dr. Albert Bourla, Chairman and CEO at Pfizer
“ I am honored to be succeeding Mikael…I am confident that we can build on our long history of successes and drive even deeper focus on advancing impactful programs. ”
Dr. Chris Boshoff, Chief Scientific Officer & President of R&D at Pfizer
